


Supplementary information, Fig. S12



Supplementary information, Fig. S12 LINE-1 inhibition reprograms the tumor microenvironment and sensitizes anti-PD-1 therapy *in vivo*.

a, b Daily average body weight (**a**) and food consumption (**b**) were monitored in BALB/c mice injected with 4T1 cells (shNC or shZnf689) and treated with EFV post-tumor emergence (n = 6 mice/group). **c** Growth curves of 4T1 and AT3 mammary tumors in mice subjected to treatment regimens with or without anti-PD-1 (n = 5 mice/group). **d** The 4T1 tumors from mice in Fig. 6e were harvested for flow cytometry to determine the percentages of CD4⁺ T cells among CD3⁺ T cells (n = 6). **e** The histologic ITH and MHC-I levels on the surface of AT3 tumors from mice in Fig. 6j (n = 6). MFI, mean fluorescence intensity. **f** The AT3 tumors from mice in Fig. 6j were harvested for flow cytometry to determine the percentages of CD4⁺ T cells among CD3⁺ T cells, CD8⁺ T cells among CD3⁺ T cells, GZMB⁺ cells among CD8⁺ T cells, and IFN- γ ⁺ cells among CD8⁺ T cells (n = 6). P values were determined using two-way ANOVA (**a-c**) and one-way ANOVA (**d-f**). ns, not significant; **p < 0.01, ***p < 0.001.